|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Depo Provera contraceptive. Updated 1/95. |
| National Women's Health Network |
| Washington, D.C., National Women's Health Network, 1995. [7], 154 p. |
| The National Women's Health Network has compiled information on Depo-Provera to provide women with accurate |
| and current information on it so they can make informed decisions. At the US Food and Drug Administration's (FDA) |
| Public Board of Inquiry in 1983, the Network testified against Depo-Provera because it causes cancer in test animals |
| and may cause cancer in humans. Depo-Provera has been used to treat menopausal systems and endometriosis |
| and as a pregnancy test, yet there have been no studies for these uses. At the 1992 FDA hearing, the Network |
| testified against FDA approval of Depo-Provera and compiled a registry of women who had used Depo-Provera and |
| had side effects. The information packet is composed of seven sections: a cover letter, table of contents, facts on |
| Depo-Provera, organizational statements of Depo-Provera and model consent form, controversy over Depo-Provera |
| use (e.g., in India and Bangladesh), medical studies and implications, and bibliography of additional articles. Other |
| than the cover letter, table of contents, and bibliography of additional articles, the sections include articles and other |
| documents about Depo-Provera use. The section on medical studies and implications present documents on breast |
| cancer, bone density, in utero exposure to Depo-Provera (e.g., in Thailand), on serum and lipoprotein lipids, on |
| cervical cancer, and an overview of medical research on Depo-Provera. The packet contains 154 pages of |
| information on Depo-Provera gathered from medical journals, magazines, the FDA, the Network, the Indian Health |
| Services, and newspapers. (PubHealth.info Document ID: CONT2T 2523-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Depo Provera contraceptive. Updated 1/95.", is(are) |
| National Women's Health Network. The source of this article is "Washington, D.C., National Women's Health |
| Network, 1995. [7], 154 p.". This article was published in 1995 in English language(s). (PubHealth.info® Document |
| ID: CONT2T 2523-06. All rights reserved with PubHealth.info) PIN: 7523 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
